

NO. 91627-R1

MAGNETOENCEPHALOGRAPHY (MEG)

Effective date: 03/2026

Last reviewed: 02/2026

Instructions for use: This document is for informational purposes only. Coverage is subject to member's specific benefits. Group specific policy will supersede this policy when applicable. Eligibility and benefit coverage are determined in accordance with the terms of the member's plan in effect as of the date services are rendered. It is not an authorization, certification, explanation of benefits, or contract. Receipt of benefits is subject to satisfaction of all terms and conditions of coverage. Priority Health's medical policies are developed with the assistance of medical professionals and are based upon a review of published and unpublished information including, but not limited to, current medical literature, guidelines published by public health and health research agencies, and community medical practices in the treatment and diagnosis of disease. Because medical practice, information, and technology are constantly changing, Priority Health reserves the right to review and update its medical policies at its discretion. Priority Health's medical policies are intended to serve as a resource to the plan. They are not intended to limit the plan's ability to interpret plan language as deemed appropriate. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment they choose to provide.

Policy scope: This medical policy outlines the clinical indications, coverage parameters, regulatory references, and guideline support for the use of magnetoencephalography (MEG) as part of the diagnostic evaluation and presurgical planning for select neurological conditions.

Related policies: None

I. MEDICAL NECESSITY CRITERIA

A. Inclusions

Priority Health considers **magnetoencephalography (MEG)** medically necessary for the following indications when the specified criteria are met.

1. Presurgical/pre-operative evaluation for drug-resistant, intractable epilepsy when standard techniques (such as magnetic resonance imaging, MRI, and electroencephalography, EEG) have not provided satisfactory locations of epileptic lesions.
2. Pre-operative localization of eloquent cortex, and/or determination of the laterality of language function, prior the surgical resection of brain tumors, vascular malformations, and other indications requiring brain resection.

B. Exclusions

Priority Health considers MEG experimental and/or investigational for all other indications.

Note: There is no relevant literature supporting MEG as initial imaging for new onset seizure disorder with or without history of trauma, known seizure disorder (with or without change in semiology, or with history of tumor) unless as defined above.

II. CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) COVERAGE DETERMINATION

Any applicable federal or state mandates will take precedence over this medical coverage policy.

Medicare: Refer to the [CMS Online Manual System \(IOMs\)](#) and Transmittals.

For the most current applicable CMS National Coverage Determination (NCD)/Local Coverage Determination (LCD)/Local Coverage Article (LCA) refer to [CMS Medicare Coverage Database](#).

The information below is current as of the review date for this policy. However, the coverage issues and policies maintained by CMS are updated and/or revised periodically. Therefore, the most current CMS information may not be contained in this document. MAC jurisdiction for purposes of local coverage determinations is governed by the geographic service area where the Medicare Advantage plan is contracted to provide the service. Please refer to the Medicare [Coverage Database website](#) for the most current applicable NCD, LCD, LCA, and CMS Online Manual System/Transmittals.

National Coverage Determinations (NCDs)	
None identified	
Local Coverage Determinations (LCDs)	
CGS Administrators, LLC	None identified
First Coast Service Options, Inc.	None identified
National Government Services, Inc.	None identified
Noridian Healthcare Solutions	None identified
Novitas Solutions, Inc.	None identified
Palmetto GBA	None identified
WPS Insurance Corporation	None identified

III. BACKGROUND

Magnetoencephalography (MEG) is a non-invasive medical test that uses a superconducting quantum interference device (SQUID) and a computer to measure neuromagnetic activity within the brain. MEG detects, records and analyzes the magnetic fields produced by electrical currents in the brain. The distribution of these magnetic fields is superimposed with an anatomical image of the brain to help identify the source of activity in the brain. A MEG study is a direct measure of brain function and an advanced method of recording and evaluating the brain while it is actively functioning.

MEG is used to identify or map:

- the functional areas of the brain, including centers of sensory, motor, language and memory activities
- the precise location of the source of epileptic seizures.

MEG studies are performed with a specialized helmet that is lined with magnetic sensors, which uses specialized software to detect and record the activity of neurons as

the patient lies still or completes a series of tasks, such as listening to a series of words or looking at pictures. An analysis of the recording, which collects both normal and abnormal brain signals, helps determine where specific activities in the brain originate. A number of different MEG systems have been approved for marketing in the United States. MEG systems are classified as Class II devices and require 510(k) clearance. A number of devices have been cleared for marketing under Product Codes OLY (magnetoencephalography) and OLX (source localization software).

MEG is intended to noninvasively measure signals produced by electrically active tissue of the brain. These signals are recorded by a computerized data acquisition system, displayed, and may then be interpreted by trained physicians to help localize these active areas. The locations may then be correlated with anatomical information of the brain. MEG is routinely used to identify the locations of visual, auditory, somatosensory, and motor cortex in the brain when used in conjunction with evoked response averaging devices. MEG is also used to non-invasively locate regions of epileptic activity within the brain. The localization information provided by MEG may be used, in conjunction with other diagnostic data, in neurosurgical planning.

No CMS National Coverage Determination (NCD) on MEG was identified.

Established clinical applications:

- Epilepsy
- Pre-operative evaluation (including language function)

The recording and localization of interictal epileptic discharges and ictal events, especially for pre-surgical planning, has become the most important clinical application of MEG. MEG can confirm a patient’s suitability for epilepsy surgery. The spatial resolution of MEG and the ability to separate nearby sources are critical advantages of MEG in the refinement of the epileptogenic zone. MEG has proven helpful for selecting good candidates for epilepsy surgery when structural brain MRI is negative and for localizing the seizure onset zone, and thus planning the surgical resection in patients with focal cortical dysplasia.

IV. GUIDELINES / POSITION STATEMENTS

Medical/Professional Society	Guideline
International Federation of Clinical Neurophysiology	IFCN-endorsed practical guidelines for clinical magnetoencephalography (MEG) (August 2018)
American Clinical Magnetoencephalography Society	Clinical Practice Guideline 1: Recording and Analysis of Spontaneous Cerebral Activity (August 2011) Clinical Practice Guideline 2: Presurgical Functional Brain Mapping Using Magnetic Evoked Fields (August 2011) Clinical Practice Guideline 3: MEG-EEG Reporting (August 2011)

V. REGULATORY (US FOOD AND DRUG ADMINISTRATION)

No relevant information located.

VI. CODING

See also [Priority Health Billing Policy No. 078 Magnetoencephalography \(MEG\)](#)

CPT/HCPCS Codes

95965 Magnetoencephalography (MEG), recording and analysis; for spontaneous brain magnetic activity (e.g., epileptic cerebral cortex localization)

95966 Magnetoencephalography (MEG), recording and analysis; for evoked magnetic fields, single modality (e.g., sensory, motor, language, or visual cortex localization)

95967 Magnetoencephalography (MEG), recording and analysis; for evoked magnetic fields, each additional modality (e.g., sensory, motor, language, or visual cortex localization) (List separately in addition to code for primary procedure)

Revenue Codes

860 Magnetoencephalography (MEG) – General

861 Magnetoencephalography (MEG) - MEG

VII. MEDICAL NECESSITY REVIEW

Prior authorization for certain drugs, devices, services and procedures may or may not be required. In cases where prior authorization is required, providers will submit a request demonstrating that a drug, service or procedure is medically necessary. For more information, refer to the [Priority Health Provider Manual](#).

VIII. APPLICATION TO PRODUCTS

Coverage is subject to the member's specific benefits. Group-specific policy will supersede this policy when applicable.

- **HMO/EPO:** This policy applies to insured HMO/EPO plans.
- **POS:** This policy applies to insured POS plans.
- **PPO:** This policy applies to insured PPO plans. Consult individual plan documents as state mandated benefits may apply. If there is a conflict between this policy and a plan document, the provisions of the plan document will govern.
- **ASO:** For self-funded plans, consult individual plan documents. If there is a conflict between this policy and a self-funded plan document, the provisions of the plan document will govern.
- **INDIVIDUAL:** For individual policies, consult the individual insurance policy. If there is a conflict between this medical policy and the individual insurance policy document, the provisions of the individual insurance policy will govern.
- **MEDICARE:** Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, this policy applies.

- **MEDICAID/HEALTHY MICHIGAN PLAN:** For Medicaid/Healthy Michigan Plan members, this policy will apply. Coverage is based on medical necessity criteria being met and the appropriate code(s) from the coding section of this policy being included on the [Michigan Medicaid Fee Schedule](#). If there is a discrepancy between this policy and the [Michigan Medicaid Provider Manual](#), the Michigan Medicaid Provider Manual will govern. If there is a discrepancy or lack of guidance in the Michigan Medicaid Provider Manual, the Priority Health contract with Michigan Medicaid will govern. For Medical Supplies/DME/Prosthetics and Orthotics, please refer to the Michigan Medicaid Fee Schedule to verify coverage.

IX. REFERENCES

Guidelines/Position Statements

1. Bagić AI, Knowlton RC, Rose DF, Ebersole JS; ACMEGS Clinical Practice Guideline (CPG) Committee. American Clinical Magnetoencephalography Society Clinical Practice Guideline 1: recording and analysis of spontaneous cerebral activity. *J Clin Neurophysiol.* 2011 Aug;28(4):348-54. doi: 10.1097/WNP.0b013e3182272fed. PMID: 21811121.
2. Bagić AI, Knowlton RC, Rose DF, Ebersole JS; ACMEGS Clinical Practice Guideline (CPG) Committee. American Clinical Magnetoencephalography Society Clinical Practice Guideline 3: MEG-EEG reporting. *J Clin Neurophysiol.* 2011 Aug;28(4):362-3. doi: 10.1097/WNO.0b013e3181cde4ad. PMID: 21811123.
3. Bagić AI, Barkley GL, Rose DF, Ebersole JS; ACMEGS Clinical Practice Guideline Committee. American Clinical Magnetoencephalography Society Clinical Practice Guideline 4: qualifications of MEG-EEG personnel. *J Clin Neurophysiol.* 2011 Aug;28(4):364-5. doi: 10.1097/WNO.0b013e3181cde4dc. PMID: 21811124.
4. Burgess RC, Funke ME, Bowyer SM, Lewine JD, Kirsch HE, Bagić AI; ACMEGS Clinical Practice Guideline (CPG) Committee,. American Clinical Magnetoencephalography Society Clinical Practice Guideline 2: presurgical functional brain mapping using magnetic evoked fields. *J Clin Neurophysiol.* 2011 Aug;28(4):355-61. doi: 10.1097/WNP.0b013e3182272ffe. PMID: 21811122; PMCID: PMC3366725.
5. Hari R, Baillet S, Barnes G, Burgess R, Forss N, Gross J, Hämäläinen M, Jensen O, Kakigi R, Mauguière F, Nakasato N, Puce A, Romani GL, Schnitzler A, Taulu S. IFCN-endorsed practical guidelines for clinical magnetoencephalography (MEG). *Clin Neurophysiol.* 2018 Aug;129(8):1720-1747. doi: 10.1016/j.clinph.2018.03.042. Epub 2018 Apr 17. PMID: 29724661; PMCID: PMC6045462.

Other references

6. [American Clinical MEG Society](#)
7. Bagić AI, Funke ME, Kirsch HE, Tenney JR, Zillgitt AJ, Burgess RC. The 10 Common Evidence-Supported Indications for MEG in Epilepsy Surgery: An Illustrated Compendium. *J Clin Neurophysiol.* 2020 Nov;37(6):483-497. doi: 10.1097/WNP.0000000000000726. PMID: 33165222.
8. Bowyer SM, Zillgitt A, Greenwald M, Lajiness-O'Neill R. Language Mapping With Magnetoencephalography: An Update on the Current State of Clinical Research and Practice With Considerations for Clinical Practice Guidelines. *J Clin Neurophysiol.* 2020 Nov;37(6):554-563. doi: 10.1097/WNP.0000000000000489. PMID: 33165228.
9. Cascino GD. Epilepsy surgery: presurgical evaluation. In: *UpToDate*, Connor RF (Ed), Wolters Kluwer. (accessed on December 11, 2025.)

10. De Tiège X, Bourguignon M, Piitulainen H, Jousmäki V. Sensorimotor Mapping With MEG: An Update on the Current State of Clinical Research and Practice With Considerations for Clinical Practice Guidelines. *J Clin Neurophysiol*. 2020 Nov;37(6):564-573. doi: 10.1097/WNP.0000000000000481. PMID: 33165229.
11. Gross J, Baillet S, Barnes GR, Henson RN, Hillebrand A, Jensen O, Jerbi K, Litvak V, Maess B, Oostenveld R, Parkkonen L, Taylor JR, van Wassenhove V, Wibral M, Schoffelen JM. Good practice for conducting and reporting MEG research. *Neuroimage*. 2013 Jan 15;65:349-63. doi: 10.1016/j.neuroimage.2012.10.001. Epub 2012 Oct 6. PMID: 23046981; PMCID: PMC3925794.
12. Hayes, Inc. Evidence Analysis Research Brief. Magnetoencephalography for Presurgical Planning in Children Undergoing Epilepsy Surgery. Hayes, Inc. February 21, 2020.
13. Hayes, Inc. Health Technology Assessment. Magnetoencephalography And Magnetic Source Imaging Of The Brain. Hayes, Inc. September 15, 2008.
14. Kasteleijn-Nolst Trenite K. Photosensitive epilepsies. In: UptoDate, Connor RF (Ed), Wolters Kluwer. (accessed on December 11, 2025.)
15. Sherry DD. Complex regional pain syndrome in children. In: UpToDate, Connor RF (Ed), Wolters Kluwer. (accessed on December 11, 2025.)
16. Shvarts V, Mäkelä JP. Auditory Mapping With MEG: An Update on the Current State of Clinical Research and Practice With Considerations for Clinical Practice Guidelines. *J Clin Neurophysiol*. 2020 Nov;37(6):574-584. doi: 10.1097/WNP.0000000000000518. PMID: 33165230.
17. Zillgitt A, Barkley GL, Bowyer SM. Visual Mapping With Magnetoencephalography: An Update on the Current State of Clinical Research and Practice With Considerations for Clinical Practice Guidelines. *J Clin Neurophysiol*. 2020 Nov;37(6):585-591. doi: 10.1097/WNP.0000000000000483. PMID: 33165231.

Past review dates: 02/2021, 02/2022, 02/2023, 02/2024, 02/2025, 02/2026

AMA CPT Copyright Statement: All Current Procedure Terminology (CPT) codes, descriptions, and other data are copyrighted by the American Medical Association.

The name "Priority Health" and the term "plan" mean Priority Health, Priority Health Managed Benefits, Inc., Priority Health Insurance Company and Priority Health Government Programs, Inc.